Manju Makhija2 Rajat Rai*1

No ORCID on file · 4 papers in corpus · active 2026

Study types

  • article 4
article 2026
RECENT ADVANCES IN SUSTAINED RELEASE DRUG DELIVERY SYSTEMS FOR ENDOMETRIOSIS THERAPY
·doi:10.5281/zenodo.20641634

Endometriosis affects 10–15% of reproductive-aged women, yet current therapies remain largely palliative and non-curative. Hormonal treatments (oral contraceptives, progestins, GnRH agonists/antagonists) suppress ovulation and menstruation …

article 2026
RECENT ADVANCES IN SUSTAINED RELEASE DRUG DELIVERY SYSTEMS FOR ENDOMETRIOSIS THERAPY
·doi:10.5281/zenodo.20626242

Endometriosis affects 10–15% of reproductive-aged women, yet current therapies remain largely palliative and non-curative. Hormonal treatments (oral contraceptives, progestins, GnRH agonists/antagonists) suppress ovulation and menstruation …

article 2026
RECENT ADVANCES IN SUSTAINED RELEASE DRUG DELIVERY SYSTEMS FOR ENDOMETRIOSIS THERAPY
·doi:10.5281/zenodo.20641633

Endometriosis affects 10–15% of reproductive-aged women, yet current therapies remain largely palliative and non-curative. Hormonal treatments (oral contraceptives, progestins, GnRH agonists/antagonists) suppress ovulation and menstruation …

article 2026
RECENT ADVANCES IN SUSTAINED RELEASE DRUG DELIVERY SYSTEMS FOR ENDOMETRIOSIS THERAPY
·doi:10.5281/zenodo.20626241

Endometriosis affects 10–15% of reproductive-aged women, yet current therapies remain largely palliative and non-curative. Hormonal treatments (oral contraceptives, progestins, GnRH agonists/antagonists) suppress ovulation and menstruation …